Logo
x

Search

Subscribe Now

galderma

Galderma’s Nemluvio (Nemolizumab) Secures the US FDA’s Approval to Treat Moderate-To-Severe Atopic Dermatitis (AD)

Galderma’s Nemluvio (Nemolizumab) Secures the US FDA’s Approval to Treat Moderate-To-Severe Atopic Dermatitis (AD)

  • December 17, 2024
Galderma Publishes the P-III (OLYMPIA 1) Trial of Nemolizumab for Prurigo Nodularis in JAMA Dermatology

Galderma Publishes the P-III (OLYMPIA 1) Trial of Nemolizumab for Prurigo Nodularis in JAMA Dermatology

  • November 29, 2024
Galderma Reports the US FDA’s Approval of Nemluvio (Nemolizumab) for Treating Prurigo Nodularis (PN)

Galderma Reports the US FDA’s Approval of Nemluvio (Nemolizumab) for Treating Prurigo Nodularis (PN)

  • August 13, 2024
Galderma Reports US FDA and EMA Filing Acceptances for Nemolizumab to Treat Prurigo Nodularis and Atopic Dermatitis; US FDA grants Priority Review in Prurigo Nodularis

Galderma Reports US FDA and EMA Filing Acceptances for Nemolizumab to Treat Prurigo Nodularis and Atopic Dermatitis; US FDA grants...

  • February 14, 2024
Galderma Receives Health Canada’s Approval for Restylane SHAYPE for Chin Augmentation

Galderma Receives Health Canada’s Approval for Restylane SHAYPE for Chin Augmentation

  • January 22, 2024
Galderma Presented P-III Trial (OLYMPIA 2) Results of Nemolizumab for the Treatment of Prurigo Nodularis at WCD 2023

Galderma Presented P-III Trial (OLYMPIA 2) Results of Nemolizumab for the Treatment of Prurigo Nodularis at WCD 2023

  • July 4, 2023
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.